A Deep Pipeline of XmAb Antibody Drug Candidates

XmAb antibodies are being developed by Xencor and our partners in 11 different programs for the treatment of life-threatening and debilitating diseases.

Our four primary XmAb Fc domains are designed to improve therapeutic antibody performance by enhancing immune regulation, cytotoxic potency, or circulating half-life or by creating bispecific antibody structures that are stable, long-acting and readily produced. The plug-and-play nature of each domain has enabled the rapid discovery of a portfolio of differentiated drug candidates with a diversity of mechanisms, targets and potential disease indications. This clinical portfolio diversity, all from a common basis in Fc domain design, creates a breadth of opportunities for Xencor.